92 related articles for article (PubMed ID: 31794956)
1. PEGylation of a glycosaminoglycan-binding, dominant-negative CXCL8 mutant retains bioactivity in vitro and in vivo.
Gerlza T; Trojacher C; Jeremic D; Krieger E; Adage T; Kungl A
Cytokine; 2020 Mar; 127():154942. PubMed ID: 31794956
[TBL] [Abstract][Full Text] [Related]
2. PA401, a novel CXCL8-based biologic therapeutic with increased glycosaminoglycan binding, reduces bronchoalveolar lavage neutrophils and systemic inflammatory markers in a murine model of LPS-induced lung inflammation.
Adage T; Del Bene F; Fiorentini F; Doornbos RP; Zankl C; Bartley MR; Kungl AJ
Cytokine; 2015 Dec; 76(2):433-441. PubMed ID: 26303011
[TBL] [Abstract][Full Text] [Related]
3. Targeting glycosaminoglycans in the lung by an engineered CXCL8 as a novel therapeutic approach to lung inflammation.
Adage T; Konya V; Weber C; Strutzmann E; Fuchs T; Zankl C; Gerlza T; Jeremic D; Heinemann A; Kungl AJ
Eur J Pharmacol; 2015 Feb; 748():83-92. PubMed ID: 25554213
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs.
Tanino Y; Coombe DR; Gill SE; Kett WC; Kajikawa O; Proudfoot AE; Wells TN; Parks WC; Wight TN; Martin TR; Frevert CW
J Immunol; 2010 Mar; 184(5):2677-85. PubMed ID: 20124102
[TBL] [Abstract][Full Text] [Related]
5. The effect of the decoy molecule PA401 on CXCL8 levels in bronchoalveolar lavage fluid of patients with cystic fibrosis.
McElvaney OJ; O'Reilly N; White M; Lacey N; Pohl K; Gerlza T; Bergin DA; Kerr H; McCarthy C; O'Brien ME; Adage T; Kungl AJ; Reeves EP; McElvaney NG
Mol Immunol; 2015 Feb; 63(2):550-8. PubMed ID: 25453468
[TBL] [Abstract][Full Text] [Related]
6. A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage.
Bedke J; Nelson PJ; Kiss E; Muenchmeier N; Rek A; Behnes CL; Gretz N; Kungl AJ; Gröne HJ
Mol Immunol; 2010 Feb; 47(5):1047-57. PubMed ID: 20004976
[TBL] [Abstract][Full Text] [Related]
7. A combinatorial approach to biophysically characterise chemokine-glycan binding affinities for drug development.
Gerlza T; Hecher B; Jeremic D; Fuchs T; Gschwandtner M; Falsone A; Gesslbauer B; Kungl AJ
Molecules; 2014 Jul; 19(7):10618-34. PubMed ID: 25054442
[TBL] [Abstract][Full Text] [Related]
8. Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo.
Falsone A; Wabitsch V; Geretti E; Potzinger H; Gerlza T; Robinson J; Adage T; Teixeira MM; Kungl AJ
Biosci Rep; 2013 Sep; 33(5):. PubMed ID: 23919527
[TBL] [Abstract][Full Text] [Related]
9. Glycosaminoglycans are important mediators of neutrophilic inflammation in vivo.
Gschwandtner M; Strutzmann E; Teixeira MM; Anders HJ; Diedrichs-Möhring M; Gerlza T; Wildner G; Russo RC; Adage T; Kungl AJ
Cytokine; 2017 Mar; 91():65-73. PubMed ID: 28011398
[TBL] [Abstract][Full Text] [Related]
10. A Requirement for Neutrophil Glycosaminoglycans in Chemokine:Receptor Interactions Is Revealed by the Streptococcal Protease SpyCEP.
Goldblatt J; Lawrenson RA; Muir L; Dattani S; Hoffland A; Tsuchiya T; Kanegasaki S; Sriskandan S; Pease JE
J Immunol; 2019 Jun; 202(11):3246-3255. PubMed ID: 31010851
[TBL] [Abstract][Full Text] [Related]
11. The Positively Charged COOH-terminal Glycosaminoglycan-binding CXCL9(74-103) Peptide Inhibits CXCL8-induced Neutrophil Extravasation and Monosodium Urate Crystal-induced Gout in Mice.
Vanheule V; Janssens R; Boff D; Kitic N; Berghmans N; Ronsse I; Kungl AJ; Amaral FA; Teixeira MM; Van Damme J; Proost P; Mortier A
J Biol Chem; 2015 Aug; 290(35):21292-304. PubMed ID: 26183778
[TBL] [Abstract][Full Text] [Related]
12. The monomer-dimer equilibrium and glycosaminoglycan interactions of chemokine CXCL8 regulate tissue-specific neutrophil recruitment.
Gangavarapu P; Rajagopalan L; Kolli D; Guerrero-Plata A; Garofalo RP; Rajarathnam K
J Leukoc Biol; 2012 Feb; 91(2):259-65. PubMed ID: 22140266
[TBL] [Abstract][Full Text] [Related]
13. Monomeric and dimeric CXCL8 are both essential for in vivo neutrophil recruitment.
Das ST; Rajagopalan L; Guerrero-Plata A; Sai J; Richmond A; Garofalo RP; Rajarathnam K
PLoS One; 2010 Jul; 5(7):e11754. PubMed ID: 20668677
[TBL] [Abstract][Full Text] [Related]
14. Truncation of CXCL8 to CXCL8(9-77) enhances actin polymerization and in vivo migration of neutrophils.
Metzemaekers M; Vandendriessche S; Berghmans N; Gouwy M; Proost P
J Leukoc Biol; 2020 Jun; 107(6):1167-1173. PubMed ID: 32272490
[TBL] [Abstract][Full Text] [Related]
15. A C-terminal CXCL8 peptide based on chemokine-glycosaminoglycan interactions reduces neutrophil adhesion and migration during inflammation.
Martínez-Burgo B; Cobb SL; Pohl E; Kashanin D; Paul T; Kirby JA; Sheerin NS; Ali S
Immunology; 2019 Jun; 157(2):173-184. PubMed ID: 31013364
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitors of protein interaction with glycosaminoglycans (SMIGs), a novel class of bioactive agents with anti-inflammatory properties.
Harris N; Kogan FY; Il'kova G; Juhas S; Lahmy O; Gregor YI; Koppel J; Zhuk R; Gregor P
Biochim Biophys Acta; 2014 Jan; 1840(1):245-54. PubMed ID: 24060749
[TBL] [Abstract][Full Text] [Related]
17. Glycosaminoglycan-Mediated Downstream Signaling of CXCL8 Binding to Endothelial Cells.
Derler R; Gesslbauer B; Weber C; Strutzmann E; Miller I; Kungl A
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29207576
[TBL] [Abstract][Full Text] [Related]
18. Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions.
Sawant KV; Poluri KM; Dutta AK; Sepuru KM; Troshkina A; Garofalo RP; Rajarathnam K
Sci Rep; 2016 Sep; 6():33123. PubMed ID: 27625115
[TBL] [Abstract][Full Text] [Related]
19. Solution NMR characterization of chemokine CXCL8/IL-8 monomer and dimer binding to glycosaminoglycans: structural plasticity mediates differential binding interactions.
Joseph PR; Mosier PD; Desai UR; Rajarathnam K
Biochem J; 2015 Nov; 472(1):121-33. PubMed ID: 26371375
[TBL] [Abstract][Full Text] [Related]
20. CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signaling.
Giblin SP; Ranawana S; Hassibi S; Birchenough HL; Mincham KT; Snelgrove RJ; Tsuchiya T; Kanegasaki S; Dyer D; Pease JE
Front Immunol; 2023; 14():1254697. PubMed ID: 37942327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
